Active Ingredient History
Amphetamine is a strong central nervous system (CNS) stimulant that is used in the treatment of attention deficit hyperactivity disorder (ADHD), narcolepsy, and obesity. It is also commonly used as a recreational drug. Amphetamine was discovered in 1887 and exists as two enantiomers: levoamphetamine and dextroamphetamine. Amphetamine properly refers to a specific chemical, the racemic free base, which is equal parts of the two enantiomers in their pure amine forms. The term is frequently used informally to refer to any combination of the enantiomers, or to either of them alone. Historically, it has been used to treat nasal congestion and depression. Amphetamine is also used as an athletic performance enhancer and cognitive enhancer, and recreationally as an aphrodisiac and euphoriant. It is a prescription drug in many countries, and unauthorized possession and distribution of amphetamine are often tightly controlled due to the significant health risks associated with recreational use. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Affect (Phase 2)
Allergy and Immunology (Phase 1)
Alzheimer Disease (Phase 4)
Amphetamine-Related Disorders (Phase 2)
Anhedonia (Phase 1)
Autism Spectrum Disorder (Phase 2)
Bipolar Disorder (Phase 2)
Central Nervous System Stimulants (Phase 2)
Cocaine-Related Disorders (Phase 2)
Conduct Disorder (Phase 4)
Deficiency Diseases (Phase 4)
Dementia (Phase 4)
Depression (Phase 4)
Drug Users (Phase 1)
Feeding and Eating Disorders (Phase 4)
Healthy Volunteers (Phase 4)
Idiopathic Hypersomnia (Phase 2)
Memory, Short-Term (Phase 2)
Methamphetamine (Phase 2)
Narcolepsy (Phase 2)
Opioid-Related Disorders (Phase 2)
Parenting (Phase 3)
Schizophrenia (Phase 2)
Stroke (Phase 4)
Substance Abuse, Oral (Phase 1)
Substance-Related Disorders (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
